Trial Profile
A Double Blind, Multi-Center, Randomized, Parallel-Group, Yearlong Study to Assess the Efficacy and Safety of 0 or 1600 mg/Day of S-2367 Administered Orally Once Daily With an Initial 6-Week Low Calorie Diet in Obese Males and Females.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 14 May 2018
Price :
$35
*
At a glance
- Drugs Velneperit (Primary)
- Indications Obesity
- Focus Therapeutic Use
- Sponsors Shionogi USA
- 24 Oct 2009 Results presented at the 2009 Annual Meeting of the North American Association for the Study of Obesity (NAASO 2009).
- 24 Feb 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 17 Feb 2009 Analysis of secondary endpoints is ongoing, according to a media release from Shionogi.